SAN FRANCISCO, California -- For the first time, the FDA has approved a medication specifically to treat new mothers who suffer from postpartum depression.
The drug is called Brexanolone and will be sold under the name Zulresso.
[Ads /]
The drug's maker, Sage Therapeutics, says only one dose is needed. Zulresso is administered in an intravenous drip that takes nearly 60 hours and is expected to cost between $20,000 to $35,000.
Clinical trials show it works within hours.
[Ads /]
The CDC says one in nine mothers suffers from postpartum depression.
----------
* Follow us on YouTube
* More local news
* Send us a news tip
* Download the abc7NY app for breaking news alerts